Home Compare QIA.DE vs REGN
Stock Comparison · Comparison

Qiagen N.V. vs Regeneron Pharmaceuticals: Which Stock Looks Stronger in 2026?

Regeneron Pharmaceuticals holds the cleaner structural position, with growth as the main driver and valuation adding further support. Qiagen still leads on profitability and stability, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (QIA.DE: HDAX, REGN: Nasdaq 100).

Updated 2026-07-05

The clearest score difference appears in growth.

Trajectory Similarity
0.67
Moderately similar
Peer-set rank: #2
within Qiagen N.V.'s functional peer set

This pair is matched through long-term financial trajectory similarity within the selected peer universe.

This level of similarity points to a meaningful structural match, though not a tight one.

Most of the shared profile comes through operating margin level and revenue stability.

Similarity drivers
operating margin levelrevenue stability
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
QIA.DE
Qiagen N.V.
58
Peer-Score
Signal qualitylow
Peer basis: HDAX
vs
REGN
Regeneron Pharmaceuticals, Inc.
65
Peer-Score
Signal qualitylow
Peer basis: Nasdaq 100

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: QIA.DE vs REGN Profitability 76 63 Stability 79 65 Valuation 66 88 Growth 0 33 QIA.DE REGN
Gap Ranking
#1 Growth +33
#2 Valuation +22
#3 Stability +14
#4 Profitability +13
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for QIA.DE and REGN Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer QIA.DEREGN Relative valuation Structural strength

Regeneron Pharmaceuticals, Inc. and Qiagen N.V. look relatively close on structure, but the price setup still leans toward Regeneron Pharmaceuticals, Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Entry today — historical context

Where QIA.DE and REGN each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY QIA.DE Lower · below norm 0th 50th 100th 29 pct gap REGN Neutral · below norm 0th 50th 100th 5th 34th
Today QIA.DE sits in the lower portion of its own 5-year history (5th percentile), while REGN sits higher in its own history (34th). Within each stock's own 5-year context, QIA.DE is at a historically more favourable entry position than REGN. This reflects entry timing, not which company is structurally stronger — peer-relative analysis is a separate question addressed above.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Growth
Both sit in the weaker half on growth, with Regeneron Pharmaceuticals, Inc. still coming out ahead.
Valuation
Both look solid on valuation, though Regeneron Pharmaceuticals, Inc. still holds the stronger peer position.
Growth — Dominant Gap
QIA.DE
0
REGN
33
Gap+33in favour of REGN

The current lead is backed by a stronger multi-year growth trajectory.

What keeps the gap from being one-sided

Stability still leans toward Qiagen N.V., so the lead is real without reading as one-way.

What this means for the comparison

Growth is the clearest driver of the lead, with valuation adding further support — though profitability still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the QIA.DE vs REGN comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-and-valuation comparisons

Explore how QIA.DE and REGN each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.